Serum levels of advanced glycation end products are associated with in-stent restenosis in diabetic patients.
The formation of advanced glycation end products (AGEs), in various tissues has been known to enhance immunoinflammatory reactions and local oxidant stresses in long standing diabetes. Recently, AGEs have been reported to play a role in neointimal formation in animal models of arterial injury. We attempted to determine whether the serum levels of AGEs are associated with coronary restenosis in diabetic patients. Blood samples were collected from diabetic patients with coronary artery disease undergoing stent implantation and the serum levels of AGEs were analyzed by the fluorescent intensity method. The development of in-stent restenosis (ISR) was evaluated by a 6-month follow-up coronary angiography. A total of 263 target lesions were evaluated, in 203 patients. The ISR rate in the high-AGE (>170 U/ml) group (40.1%) was significantly higher than in the low-AGE group (<or=170 U/ml) (19.6%) (p<0.001). Furthermore, multivariate analysis revealed that a high level of serum AGEs is an independent risk factor for the development of ISR (odds ratio, 2.659; 95% CI, 1.431-4.940; p=0.002). The serum levels of AGEs constitute an excellent predictive factor for ISR, and should be one of the guidelines for medical therapy and interventional strategy to prevent ISR in diabetic patients.
Choi
Eui-Young
EY
Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea.
Kwon
Hyuck Moon
HM
Ahn
Chul-Woo
CW
Lee
Geun Taek
GT
Joung
Boyoung
B
Hong
Bum Kee
BK
Yoon
Young Won
YW
Kim
Dongsoo
D
Byun
Ki-Hyun
KH
Kang
Tae Soo
TS
Yoon
Se-Jung
SJ
Kwon
Sung Woo
SW
Lee
Sung-Ju
SJ
Park
Jong-Kwan
JK
Kim
Hyun-Seung
HS
D000368:Aged; D003324:Coronary Artery Disease / Q000453:epidemiology / Q000378:metabolism* / Q000628:therapy*; D023903:Coronary Restenosis / Q000453:epidemiology / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology / Q000378:metabolism*; D005260:Female; D017127:Glycation End Products, Advanced / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D015607:Stents
D017127:Glycation End Products, Advanced
Am J Kidney Dis. 2002 Sep;40(3):464-71
12200796
J Chromatogr B Biomed Sci Appl. 1999 Aug 6;731(1):23-36
10491986
Circulation. 2003 May 6;107(17):2238-43
12719284
N Engl J Med. 2003 Jun 5;348(23):2294-303
12788993
Arterioscler Thromb Vasc Biol. 2003 Nov 1;23(11):2027-33
14500292
Circ Res. 2003 Dec 12;93(12):1159-69
14670831
Circulation. 2004 Feb 24;109(7):867-73
14757691
JAMA. 1979 May 11;241(19):2035-8
430798
N Engl J Med. 1988 May 19;318(20):1315-21
3283558
J Mol Biol. 1988 Sep 20;203(2):495-505
3143838
Circulation. 1990 Oct;82(4):1193-202
2401060
J Biol Chem. 1992 Jun 25;267(18):12404-7
1618745
Clin Chem. 1997 Sep;43(9):1563-9
9299934
Circulation. 1997 Sep 2;96(5):1454-60
9315531
J Am Coll Cardiol. 1998 Jan;31(1):224-30
9426044
J Clin Invest. 2003 Apr;111(7):959-72
12671045